UMG 2032

In research, the UMG continues to focus and develop its profile with research priorities in neurosciences, cardiovascular medicine, molecular cell biology and oncology through the unifying, cross-organ and cross-disease concept of metabolic plasticity. We want to increase the number of collaborative projects coordinated and funded at the UMG by 2032 and remain one of the ten strongest research institutions in university medicine in Germany.

We will continue to strategically drive forward these goals, for instance as part of the project ‘Potenziale strategisch entfalten: UMG 2032 - Excellence through Focus’.

We are continuously developing our teaching and our teaching staff and sharpening our teaching profile through clear qualitative criteria. In 2032, students at the UMG will complete a degree program in which teaching is interdisciplinary and future-oriented and in which various degree programs and professions are more interconnected. By training all healthcare professions in basic degree programs at the Göttingen Health Campus, this further development will benefit all therapeutic professions.

We will continue to strategically drive forward these goals, for instance as part of the project ‘Potenziale strategisch entfalten: UMG 2032 - Excellence through Focus’.

In health care, we will have consolidated our reputation for excellent university maximum care by 2032 and will be well established among patients and referring physicians both regionally and nationally. We will have expanded our range of complex university treatments and strengthened regional networking through cooperation with other hospitals and healthcare providers - also in innovative cross-sector concepts. We will continuously increase outpatient care, patient safety and service quality in order to guarantee the best scientifically sound medical care for all.

We see networking and, in particular, cooperation with other academic institutions, local authorities and industry in the Göttingen life science ecosystem as a unique selling point for the UMG. We will use this to build up a nationally and internationally recognized, outstanding reputation in the field of technology transfer by 2032. We will provide comprehensive support for the development of project ideas and applications into products, applications or new drugs, from licensing to spin-offs.

We will continue to strategically drive forward these goals, for instance as part of the project ‘Potenziale strategisch entfalten: UMG 2032 - Excellence through Focus’.

Our employees are the key to ensuring a high level of research, teaching, healthcare and transfer and to providing administrative support. We therefore want to “attract and retain” excellent and motivated employees in all areas and provide incentives through structured training programs and career opportunities, thereby positioning the UMG as an attractive employer. Our people-oriented culture of values will be more firmly anchored in our daily interactions with employees and patients and will be integrated into everyday life by 2032.

Through increasing digitalization, the UMG is modernizing all processes for the benefit of patients and employees. The UMG's digital transformation will further optimize research, teaching, healthcare and transfer. The UMG is supporting its patients and regional care partners with more telemedicine applications. With our data center, we want to be a leading regional, national and international data provider for research and healthcare. Artificial intelligence methods are increasingly being developed, acquired as products and used in a quality-assured manner.

The basis for the implementation of “UMGestalten 2032” is a permanently healthy economic situation and the associated ability to act. Our goal is to achieve a sustainably stable financial situation with a balanced or positive operating result year after year by 2032, in order to be able to spend a total of ten million euros on self-financed investments by 2032.